Oral racemic methadone HCl

PreclinicalSmall molecule

WWashington University School of Medicine

Oral racemic methadone HCl is one of 4 small molecule programs targeting Methadone. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MethadoneCompleted

MethadonePreclinical

Completed

Competition

Competitive Landscape

4 competitors in Methadone

#DrugCompanyPhaseTrials

Isentress

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 2

Oxycontin

PPurdue Pharma LP

Preclinical

1 3

IV Vancomycin

MMelinta Therapeutics, Inc.

Preclinical

1 4

Oral racemic methadone HCl

WWashington University School of Medicine

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Methadone1 trial

CYP2B6 Polymorphisms in Methadone Disposition

Completed·WWashington University School of Medicine·N/A·NCT01648283·78 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Oral racemic methadone HCl. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Oral racemic methadone HCl compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Oral racemic methadone HCl. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Washington University School of Medicine company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: WWashington University School of Medicine

Oral racemic methadone HCl

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Methadone1 trial

References

Drug Info

Quick Facts

Related News